Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (151-160 of 317) with videos related to

Pageof 32
Sort By:
Nature Reviews. Immunology|October 2, 2019
Defining 'T cell exhaustion'Christian U Blank, W Nicholas Haining, Werner Held, et al.
Nature Medicine|November 13, 2023
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanomaItske Fraterman, Irene L M Reijers, Petros Dimitriadis, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Trials|February 14, 2022
Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trialT M L Tong, M K van der Kooij, F M Speetjens, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
BMC Cancer|December 30, 2022
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trialJ S W Borgers, F H Burgers, E M Terveer, et al.
Communications Medicine|October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanomaJudith M Versluis, Huma Shehwana, Robert Elens, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Pageof 32

Showing results (151-160 of 317) with videos related to

Sort By:
Pageof 32
Nature Reviews. Immunology|October 2, 2019
Defining 'T cell exhaustion'Christian U Blank, W Nicholas Haining, Werner Held, et al.
Nature Medicine|November 13, 2023
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanomaItske Fraterman, Irene L M Reijers, Petros Dimitriadis, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
Trials|February 14, 2022
Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trialT M L Tong, M K van der Kooij, F M Speetjens, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
BMC Cancer|December 30, 2022
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trialJ S W Borgers, F H Burgers, E M Terveer, et al.
Communications Medicine|October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanomaJudith M Versluis, Huma Shehwana, Robert Elens, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Pageof 32